The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 27, 2015
Filed:
Oct. 17, 2011
Kyeong Lee, Seoul, KR;
MI Sun Won, Daejeon, KR;
Hwan Mook Kim, Daejeon, KR;
Song Kyu Park, Daejeon, KR;
Kiho Lee, Daejeon, KR;
Ki Hoon Lee, Daejeon, KR;
Chang Woo Lee, Daejeon, KR;
Jung Joon Lee, Daejeon, KR;
Kyung Sook Chung, Daejeon, KR;
BO Kyung Kim, Daejeon, KR;
Yinglan Jin, Seoul, KR;
Seung-hee Lee, Daejeon, KR;
Kyeong Lee, Seoul, KR;
Mi Sun Won, Daejeon, KR;
Hwan Mook Kim, Daejeon, KR;
Song Kyu Park, Daejeon, KR;
Kiho Lee, Daejeon, KR;
Ki Hoon Lee, Daejeon, KR;
Chang Woo Lee, Daejeon, KR;
Jung Joon Lee, Daejeon, KR;
Kyung Sook Chung, Daejeon, KR;
Bo Kyung Kim, Daejeon, KR;
Yinglan Jin, Seoul, KR;
Seung-hee Lee, Daejeon, KR;
Abstract
The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.